Evidence map›Paper›PMID 39040065›Full record

ArticleiScience2024

Mesoporous manganese nanocarrier target delivery metformin for the co-activation STING pathway to overcome immunotherapy resistance.

Yuanyao Dou, Jie Zheng, Jun Kang, Liping Wang, Daijuan Huang, Yihui Liu, Chao He, Caiyu Lin, Conghua Lu, Di Wu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuanyao DouKey Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
Jie ZhengDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Jun KangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Liping WangDepartment of pain treatment, the seventh people's Hospital of Chongqing, Chongqing 401320, China.
Daijuan HuangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Yihui LiuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Chao HeDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Caiyu LinDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Conghua LuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Di WuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Rui HanDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Li LiDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.
Liling TangKey Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
Yong HeDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing 400042, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting the stimulator of interferon genes (STING) pathway is a promising strategy to overcome primary resistance to immune checkpoint inhibitors in non-small cell lung cancer with the STK11 mutation. We previously found metformin enhances the STING pathway and thus promotes immune response. However, its low concentration in tumors limits its clinical use. Here, we constructed high-mesoporous Mn-based nanocarrier loading metformin nanoparticles (Mn-MSN@Met-M NPs) that actively target tumors and respond to release higher concentration of Mn

Indexed as

BiomaterialsDrug delivery system

Identifiers

PMID39040065
PMCPMC11261061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.